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ABSTRACT
Purpose Overexpression of miR-100 in stem cells derived 
from basal- like breast cancers causes loss of stemness, 
induction of luminal breast cancer markers and response 
to endocrine therapy. We, therefore, explored miR-100 as a 
novel biomarker in patients with luminal breast cancer.
Methods miR-100 expression was studied in 90 patients 
with oestrogen- receptor- positive/human- epidermal 
growth factor receptor 2- negative breast cancer enrolled 
in a prospective study of endocrine therapy given either 
preoperatively, or for the treatment of de novo metastatic 
disease. Response was defined as a Ki67 ≤2.7% after 
21±3 days of treatment. The prognostic role of miR-100 
expression was evaluated in the Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC) and 
The Cancer Genome Atlas (TCGA) breast cancer datasets. 
Additionally, we explored the correlation between miR-100 
and the expression its targets reported as being associated 
with endocrine resistance. Finally, we evaluated whether 
a signature based on miR-100 and its target genes could 
predict the luminal A molecular subtype.
Results Baseline miR-100 was significantly anticorrelated 
with baseline and post- treatment Ki67 (p<0.001 and 0.004, 
respectively), and independently associated with response 
to treatment (OR 3.329, p=0.047). In the METABRIC dataset, 
high expression of miR-100 identified women with luminal 
A tumours treated with adjuvant endocrine therapy with 
improved overall survival (HR 0.55, p<0.001). miR-100 was 
negatively correlated with PLK1, FOXA1, mTOR and IGF1R 
expression, potentially explaining its prognostic effect. Finally, 
a miR-100- based signature developed in patients enrolled in 
the prospective study outperformed Ki67 alone in predicting 
the luminal A phenotype.
Conclusions Our findings suggest that miR-100 should 
be further explored as a biomarker in patients with luminal 
breast cancer.
INTRODUCTION
Breast cancer is the most frequent malignancy 
and the second cause of cancer death in the 
female sex.1 About 70% of newly diagnosed 
operable breast cancers express hormone 
receptors and have a normal human- 
epidermal growth factor receptor 2 (HER2) 
status.2 By gene expression analysis, these 
tumours can be further stratified into two 
molecular phenotypes. So- called luminal A 
tumours are slowly proliferating, carry a good 
prognosis, and are highly sensitive to endo-
crine therapy. Conversely, luminal B tumours 
present higher proliferation, relative endo-
crine resistance, and often require chemo-
therapy as part of postsurgical therapy.3 4 
Despite substantial benefits of adjuvant endo-
crine therapy on disease- free and overall 
survival (OS), several women with luminal 
tumours still experience metastatic recur-
rence.5 Identifying biomarkers of sensitivity 
Key questions
What is already known about this subject?
 ► We demonstrated that miR-100 levels are associ-
ated with response to endocrine therapy in women 
with operable luminal breast cancers.
What does this study add?
 ► We found miR-100 levels to stratify luminal A tu-
mours into two prognostically different subgroups.
 ► The role of miR-100 as a post- transcriptional reg-
ulator of genes implicated in endocrine resistance 
and prognosis in luminal breast cancer may explain 
miR-100 predictive and prognostic ability. A signa-
ture based on four biomarkers, including miR-100, 
was accurate and reproducible in predicting the lu-
minal A phenotype.
How might this impact on clinical practice?
 ► miR-100 appears as a promising biomarker in early, 
luminal breast cancer and should be studied further.
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or resistance to endocrine therapy is, therefore, a priority 
in breast cancer research.
MicroRNAs (miRNAs) are short, non- coding RNA mole-
cules that act as negative regulators of gene expression at 
the post- transcriptional level. Alterations in miRNA func-
tions have been implicated in a variety of human diseases, 
including cancer.6 Additionally, due to high stability in 
serum, circulating miRNAs are emerging as promising 
tumour biomarkers.7–10 MiR-100, a member of the miR-99 
family, has been found to post- transcriptionally suppress 
several downstream effectors involved in cancer cell 
proliferation, apoptosis, invasion and cell cycle arrest.11 
Clinical data point at a potential of either tumour or 
circulating miR-100 in cancer detection and outcome 
prediction.12–15 Interestingly, miR-100 has been found 
to post- transcriptionally downregulate mTOR, FOXA1, 
PLK1, FGFR3 and IGF1R.16–19 These genes, in turn, have 
been described as mediators of resistance to endocrine 
therapy in luminal cancers.20–26
Added to this background, we previously demonstrated 
that the ectopic expression of miR-100 in cancer stem 
cells derived from aggressive, basal- like breast cancers 
(hormone receptors and HER2 negative) caused loss of 
stemness, and induction of cytokeratins 8–18 (markers of 
luminal breast cancer cells) and oestrogen receptor (ER) 
expression.27 Not only was this evolution phenotypical, 
but also functional because the acquisition of hormone 
receptor expression resulted in an endocrine- sensitive 
status. We, therefore, hypothesised that miR-100 could be 
a clinically exploitable biomarker in women with luminal 
breast cancer. To substantiate this hypothesis, we designed 
a prospective study to address the following questions: 
(1) are increasing tumour levels of miR-100 associated 
with response to endocrine therapy administered in the 
preoperative setting?; (2) are increasing levels of miR-100 
prognostic beyond the tumour molecular phenotype 
(luminal A and luminal B); (3) is miR-100 expression 
correlated with the expression of genes that are known 
to influence response to endocrine therapy?; (4) could 
the expression on miR-100 and its target genes help to 
distinguish between luminal A and luminal B tumours in 
the clinic? Here, we present the results of our study.
METHODS
Patients
The ‘REporting recommendations for tumour MARKer 
prognostic studies’ checklist for this study is found in 
online supplemental material.28
A single- arm, non- randomised, monoinstitutional clin-
ical study was designed to explore miR-100 as a predictor 
of response to endocrine therapy (BC- P1-13, (online 
supplemental table 1). To be eligible for the study women 
had to be at their first diagnosis of hormone- receptor- 
positive, HER2- negative breast cancer with a baseline 
Ki67 ≥5% and to belong to one of the following three 
groups: (1) candidates to immediate breast surgery; (2) 
candidates to neoadjuvant endocrine therapy to induce 
tumour regression before surgery; (3) candidates to first- 
line endocrine therapy for primary breast cancer with 
synchronous distant metastases (de novo metastatic). 
Treatment consisted of tamoxifen 20 mg/day or letro-
zole 2.5 mg/day in premenopausal and postmenopausal 
women, respectively. Ovarian function suppression was 
allowed in premenopausal patients in groups 2 and 3. 
Treatment was planned to be 3 weeks in women in group 
1, 4–6 months in women in group 2, and as long as clini-
cally indicated in women in group 3. All women included 
in this study were managed by the multidisciplinary breast 
clinic of the Candiolo Cancer Institute, FPO- IRCCS.
Two baseline tumour core biopsies were obtained for 
all patients. In one of the baseline core biopsies, ER, PgR, 
HER2, and tumour proliferation (Ki67 score) were deter-
mined at our Pathology Department by conventional 
immunohistochemistry (IHC) on routinely processed, 
formalin- fixed, paraffin- embedded tumour specimens. 
Patients with HER2 2+status could enter the study if 
fluorescence in situ hybridisation excluded HER2 ampli-
fication. The second baseline biopsy was preserved in 
RNAlater and processed for miRNA and gene expression 
evaluation at our Cancer Molecular Biology Unit.
Subsequently, Ki67 was evaluated on surgical specimens 
in patients in group 1, and on tumour core biopsy taken 
after 21±3 days of treatment in women in groups 2 and 
3. Therefore, all patients were planned to have tumour 
proliferation assessed after a short exposure of about 
3 weeks of endocrine therapy.
The key findings from the BC- P1-13 study were further 
explored in two publicly available gene- expression data-
sets (METABRIC and TCGA),29 30 and in an Institutional 
retrospective cohort consisting of 77 randomly selected 
archival primary luminal tumour samples from women 
treated with surgery followed by adjuvant treatments 
including endocrine therapy at the Candiolo Cancer 
Institute between 2006 and 2010 (online supplemental 
table 2). This latter cohort was assembled to test whether 
formalin- fixed, paraffine- embedded archival material 
could be suitable for the evaluation of miR-100 and its 
relationship with the luminal subtypes.
Evaluation of miR-100 levels, target gene expression and 
PAM50
For the BC- P1-13 prospective study, total RNA was 
extracted from fresh tissue of core biopsies (median 
tumour cellularity 60%, range 25%–85%) using the 
miRNeasy Mini Kit (Qiagen) and following manufac-
turer’s instructions. For the archival cohort, total RNA 
was extracted from formalin- fixed paraffine- embedded 
(FFPE) sample sections after dissection of tumour tissue, 
using the miRNeasy FFPE Kit (Qiagen). For miRNA eval-
uation, 20 nanograms of RNA from each sample were 
reverse- transcribed using the microRNA Reverse Tran-
scription Kit, and miRNA levels were assessed by quan-
titative qRT- PCR using the specific TaqMan microRNA 
Assay (Applied Biosystems). The microRNA let- 7d- 5p was 
used as an endogenous control to normalise miR-100 
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expression in each sample since, from an in silico analysis 
conducted on the TCGA breast cancer dataset, it showed 
high expression and low IQR among patients’ tumours.31 
Total RNA extracted from a breast cancer cell line (MDA- 
MB-486) was used as a reference RNA and analysed in 
every qRT- PCR in parallel with tumour samples. MiR-100 
expression in each tumour sample was then compared 
with miR-100 expression in the reference RNA and 
reported as log2 fold change (-∆∆CT sample/reference) 
in all the statistical analyses. For the evaluation of FOXA1, 
PLK1, mTOR, IGF1R and FGFR3 expression, 200 ng of 
RNA from each sample were used for reverse transcrip-
tion with the high capacity cDNA reverse transcription 
Kit, and gene expression was assessed using specific 
TaqMan probes (Applied Biosystems). Beta- actin was 
used as a housekeeping gene. Gene expression in each 
sample was compared with gene expression in the refer-
ence RNA and reported as log2 fold change, as described 
for miR-100 analysis.
The molecular subtype classification was carried out 
on the BC- P1-13 and archival cohorts using a minimum 
of 150 ng/sample of total RNA with the PAM50 gene 
signature panel on the nCounter FLEX Analysis System 
(NanoString Technologies), following manufactur-
er’s instructions. Intrinsic subtype classification was 
performed by the NanoString Technologies’ service.
Statistical methods
Because the role of miR-100 as a determinant of endocrine 
responsiveness is exploratory, we sized the BC- P1-13 study 
on the primary end- point of complete cell cycle arrest 
(CCCA, defined as a post- treatment Ki67 ≤2.7%).32 Because 
this threshold corresponded to the lowest tertile of the 
normal logarithm of Ki67 scores after a short treatment, 
it is suggested that about 30%–35% of hormone receptor- 
positive tumours could be defined as endocrine responsive 
at this time point. Therefore, the clinical trial was sized to 
confirm a 30% proportion of endocrine- responsive patients 
with a beta error of 10% and an alpha error of 5%. Consid-
ering a possible dropout rate of 10%, the final trial size was 
established at 88 patients to be enrolled in 24 months. After 
a first interim analysis, because no patient on tamoxifen 
achieved a CCCA, the protocol was amended to include 
only postmenopausal patients assigned to letrozole 2.5 mg/
Figure 1 MiR-100 expression negatively correlates with proliferation and is higher in patients achieving complete cell cycle 
arrest. Scatter plots with Spearman correlation coefficients (ρ) between miR-100 expression in baseline tumour biopsies 
and either (A) baseline Ki67 or (B) post- treatment Ki67 (post- Tx Ki67); the logarithmic scale is used on the ordinate axis. (C) 
Boxplots with p value from Mann- Whitney U test for baseline miR-100 expression in responder and non- responder patients. 
The line within the box, boundaries and whiskers indicate median, IQR and 1.5 times the IQR, respectively. Non- R, non 
responder; R, responder.
Table 1 Univariable and multivariable analysis of predictors 
of complete cell cycle arrest
Variable OR 95% CI P value
Univariable
  Histology 0.811
  Ductal 1
  Lobular 1.418 0.473 to 4.225
  Other 1.261 0.232 to 6.842
  Grade 0.001
  G1 1
  G2/G3 0.258 0.113 to 0.588
  ER (continuos) 1.414 0.222 to 8.999 0.713
  PgR (continuous) 1.010 0.998 to 1.022 0.118
  Subtype
  Non- Luminal A 1 <0.001
  Luminal A 6.389 2.302 to 17.732
  Baseline Ki67* 0.250 0.112 to 0.559 <0.001
  miR-100 (upper 
quartile vs others)
5.143 1.822 to 14.518 0.002
Multivariable
  Baseline Ki67* 0.289 0.127 to 0.656 0.003
  miR-100 (upper 
quartile vs others)
3.329 1.015 to 12.974 0.047
*Ki67 values were log2 transformed.
ER, oestrogen receptor.
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day. We conducted post hoc analyses using different defini-
tions of proliferative response, as log- fold of Ki67 change, 
percentage reduction of Ki67 (exploring various cutoffs), 
and geometric mean reduction. All the participants had to 
sign an informed consent before being considered for the 
study procedures.
The predictive value of miR-100 for CCCA after short- 
term endocrine therapy was evaluated by logistic regression 
analysis considering baseline Ki67 expression, histological 
type, grade, ER expression, progesterone receptor expres-
sion, and molecular phenotype as co- variates. Because the 
baseline Ki67 values were not distributed normally, they 
were log2- transformed. A dichotomised post- treatment Ki67 
variable was generated using 2.7% of positivity as the cut- off. 
Pretreatment variables that resulted statistically significant 
in the univariable setting were entered in the multivariable 
analyses. Logistic regression analysis was also used to build 
a prediction model of luminal A molecular subtype; in 
this case, the dichotomous dependent variable was created 
according to the samples’ PAM50 classification as luminal 
A or not. Variables identified as statistically significant in 
univariable analysis were then evaluated in the multiple 
logistic regression analysis combining miR-100 and its target 
genes expression level into a score. Expression level scores 
for the prediction of the luminal A molecular phenotype 
were generated by subtracting either the single target gene 
or the mean of the two target genes expression values from 
miR-100 level as follows:
 Score = miR100 − PLK1 
 Score = miR100 − FOXA1 
 Score = miR100 − PLK1 + FOXA1 
The best model was selected as the one with the 
minimum Akaike information criterion value and was 
tested via analysis of variance (ANOVA) test. To evaluate 
the predictive performance of the model, the area under 
the receiver operating characteristic curve (AUC- ROC) 
and the Youden’s index (J=sensitivity + specificity −1) 
were used as accuracy estimators.
The developed optimal predictive model was vali-
dated in an institutional archival cohort (online supple-
mental table 2) as well as in the public METABRIC 
dataset (EGAD00010000434 and EGAD00010000438 for 
normalised mRNA and miRNA expression, respectively). 
Clinical data including PAM50 subtyping were down-
loaded from cBioPortal. Due to methodological differ-
ences in assessing predictive variables (miR-100, PLK1, 
FOXA1 and Ki67 were analysed by using gene microar-
rays in the public study), METABRIC data were split in 
training (N=509) and validation sets (N=261) focusing on 
luminal patients (N=770) according to PAM50 classifica-
tion. In this case, the model was first fitted in the training 
set and then used to predict the luminal A subtype in the 
validation set using the same covariates of the best model 
previously described in the BC- P1-13 prospective study. 
The AUC was evaluated in both sets and in the retrospec-
tive study as a readout of the model performance.
Kaplan- Meier survival estimate was employed to assess 
the difference in survival rates between patients with 
high and low miR-100 expression using the median as 
cut- off. This survival analysis was performed in hormonal 
therapy- treated patients with ER positive status (assessed 
by IHC) or luminal PAM50 subtype (A vs B). The signif-
icance was determined using the log- rank test and HRs 
were estimated using Cox regression analysis.
All analyses were performed using the statistical software 
R V.3.4.4 (http://www. R- project. org) and its packages 
‘ROCR’, ‘Survival’ and ‘Survminer’. Where appropriate, 
statistical tests were two sided. Statistical significance was 
defined as p<0.05.
Figure 2 MiR-100 predicts prognosis in endocrine therapy treated patients and identifies two subpopulations of luminal A 
patients with different survival. Kaplan- Meier curves of overall survival in (A) the ER- positive overall population (as determined 
by IHC), (B) luminal A and (C) luminal B patient subgroups (as determined by PAM50) who underwent endocrine therapy in 
the METABRIC dataset, stratified by median miR-100 expression level. P values were calculated by the log- rank test. ER, 
oestrogen receptor; IHC, immunohistochemistry.
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RESULTS
Patient disposition in the BC-P1-13 cohort
The predictive value of baseline tumour levels of miR-100 
with respect to response to endocrine therapy was 
explored in a prospective study of presurgical endocrine 
therapy (BC- P1-13, details in the Methods section). A 
total of 124 patients were screened between May 2014 and 
October 2017 and, of these, 90 patients and 90 tumours 
were evaluable for this analysis. (online supplemental 
material, figure 1) describes the enrolment flow and the 
reasons for the exclusion of 34 patients from further anal-
yses. Online supplemental table 1 summarises the rele-
vant patient demographics and tumour characteristics.
Molecular subtype classification was performed by 
PAM50 analysis on pretreatment biopsies in 89 tumours 
and revealed that 41 tumours were luminal A (46%), 44 
luminal B (50%), 3 basal- like (3%) and 1 HER2 enriched 
(1%). There was no difference in the relative frequency 
of luminal A and luminal B tumours in premenopausal 
and postmenopausal patients (χ2 test, p=0.315). The 
four non- luminal tumours were all in postmenopausal 
patients.
MiR-100 expression level is an independent predictor of 
response to endocrine therapy
After short- term treatment with either tamoxifen or 
letrozole (21 days±3), the median Ki67 was 4.9% (range 
0.2%–77.6%). Online supplemental figure 2 shows Ki67 
before and after treatment in all 90 tumours (A) and in 
tumours treated with either letrozole or tamoxifen (B 
and C, respectively).
Overall, 35 patients (39%) achieved a CCCA (95% 
CI 29% to 50%), 23 of whom had a luminal A (56%), 
and 12 a luminal B tumour (25%, χ2 test, p=0.003). No 
tumours in premenopausal patients treated with tamox-
ifen achieved a CCCA. Of the four non- luminal cancers, 
none showed CCCA.
In 90 tumours analysed, the median baseline miR-100 
value was 3.736 (log2 fold change with respect to the refer-
ence, range 0.986–5.771). Values were not significantly 
different between premenopausal and postmenopausal 
patients (3.727 vs 3.760, respectively, p=0.777). MiR-100 
levels showed a statistically significant negative correlation 
with both baseline and post- treatment Ki67 values in the 
overall population (figure 1A,B) and in postmenopausal 
patients receiving letrozole (online supplemental figure 
3A,B). Correlations between miR-100 and other histopatho-
logical variables are shown in online supplemental table 3).
Median miR-100 values were significantly higher in 
CCCA responders compared with non- responders, both 
in the overall population (figure 1C) and in postmeno-
pausal patients receiving letrozole (online supplemental 
figure 3C). Indeed, univariable logistic regression analysis 
showed that the increase of miR-100 expression was signifi-
cantly associated with CCCA in the overall population (OR 
1.852, 95% CI 1.094 to 3.134, p=0.022). Corresponding 
values in the postmenopausal population receiving letro-
zole were OR 2.119, 95% CI 1.208 to 3.719 (p=0.009). 
We then looked for a suitable miR-100 cut- off that could 
discriminate between responders and non- responders. 
We identified the value of 4.264, corresponding to the 
75th percentile of miR-100 values, and used it to dichot-
omise miR-100 (upper quartile vs others). We performed 
univariable and multivariable logistic regression analysis 
looking for predictors of CCCA (table 1). From these 
analyses, we excluded women treated with tamoxifen 
as no CCCA was observed in premenopausal patients 
receiving tamoxifen. Only baseline Ki67 values and 
miR-100 (upper quartile vs others) resulted significantly 
and independently associated with CCCA in multivari-
able analysis (table 1). Finally, in the overall population, 
we found a statistically significant higher Ki67 geometric 
mean reduction after treatment in patients in the upper 
quartile of miR-100 expression (−78.1%, 95% CI −68.1% 
to −89.7%), compared with the others (−40.5%, 95% CI 
−29.7% to −55.0%, p=0.018). Notably, the per cent reduc-
tion in Ki67 was not correlated with baseline Ki67 (online 
supplemental figure 4).
MiR-100 is associated with prognosis in patients with breast 
cancer treated with adjuvant hormonal therapy
The correlation of miR-100 with the response to short- 
term endocrine therapy, suggests a potential association 
with long- term clinical outcomes in patients with Luminal 
breast cancer receiving adjuvant endocrine therapy. We 
interrogated the METABRIC dataset to evaluate the 
prognostic value of miR-100 expression in 719 ER- posi-
tive patients with breast cancer who underwent systemic 
hormonal therapy. As shown in the Kaplan- Meier plot 
(figure 2A), a high expression of miR-100 (above the 
median value) was associated with improved OS (HR 
0.69; 95% CI 0.57 to 0.85; log- rank p<0.001). Notably, 
miR-100 levels identified two prognostically different 
luminal A patient subgroups (HR 0.55; 95% CI 0.41 to 
0.76; p<0.001, figure 2B), whereas no effect was seen in 
luminal B patients (figure 2C). MiR-100 levels were prog-
nostic in the ER- positive population of the TCGA dataset 
as well (HR 0.5; 95% CI 0.29 to 0.86; p=0.01; online 
supplemental figure 5).
MiR-100 regulates the expression of genes involved in 
resistance to hormonal therapy
After observing that baseline tumour miR-100 expression 
predicts response to short- term hormonal therapy and 
long- term prognosis, we were interested in identifying 
potential molecular mechanisms that could explain its 
predictive and prognostic value. Previously published 
data demonstrated that mTOR, FOXA1, PLK1, FGFR3 
and IGF1R are implicated in endocrine resistance and 
prognosis in HR- positive patients with breast cancer.20–26 
All these genes have been reported to be miR-100 
targets.16–19 In this scenario, we hypothesised that high 
miR-100 levels could downregulate the expression of 
mTOR, FOXA1, PLK1, FGFR3 and IGF1R, thus contrib-
uting to a better therapeutic response and outcome. 
We assessed the expression of the five genes in baseline 
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tumour biopsies by quantitative RT- PCR and performed 
a Spearman correlation analysis with miR-100 levels. In 
line with our hypothesis, the expression levels of miR-100 
and PLK1, FOXA1 and mTOR were inversely correlated 
with high statistical significance (figure 3). Of note, the 
outlier sample in the FOXA1/miR-100 anti- correlation 
plot was a basal- like tumour. IGF1R expression was also 
negatively correlated with miR-100, although the anticor-
relation did not reach statistical significance. Finally, no 
significant correlation was seen with FGFR3 (not shown). 
None of these genes was significantly correlated with 
baseline Ki67, except for PLK1, which showed a signifi-
cant positive correlation (Spearman’s correlation coeffi-
cient 0.703, p<0.001).
Association of a miR-100-based signature with the luminal A 
molecular subtype
When genomic tests are not available, the expression of 
Ki67 is used to approximate the tumour subtype (luminal 
A, low vs luminal B, high values) in women with HR- pos-
itive/HER2- negative early breast cancer to tailor treat-
ments.2 33 We hypothesised that miR-100 and its corre-
lated genes could provide additional predictive value to 
distinguish between luminal A and luminal B tumours. As 
expected, miR-100 expression was significantly higher in 
luminal A than in luminal B tumours stratified by PAM50 
analysis, both in the BC- P1-13 patients, and in an archival 
institutional cohort of 77 breast cancer specimens from 
patients with luminal cancers (figure 4A). Similar results 
were obtained by analysing the METABRIC dataset 
(figure 4B).
We then performed univariable and multivariable analyses 
of predictors of the luminal A molecular subtype, including 
histology, tumour grade, ER expression, PgR expression, 
baseline Ki67, miR-100 and the five miR-100 target genes. 
Baseline Ki67, miR-100, PLK1 and FOXA1 were significant 
predictors of the luminal A subtype (online supplemental 
table 4). By combining these markers, we developed a 
model for predicting the luminal A subtype that, based on 
ROC curve analyses, outperformed Ki67 with a 15% higher 
sensitivity and an AUC of 0.91 vs 0.87 in the BC- P1-13 cohort 
(Youden’s index 0.74 vs 0.63; figure 4C and online supple-
mental figure 6A). This improvement in predicting power 
was statistically significant (ANOVA p<0.001). The predic-
tive ability of the model was independently confirmed in 
Figure 3 MiR-100 negatively correlates with the expression of target genes involved in endocrine therapy resistance. Scatter 
plots with Spearman correlation coefficients (ρ) and p values between the expression of miR-100 and its target genes in 
baseline tumour biopsies. The outlier sample in the miR-100/FOXA1 plot corresponds to a basal- like tumour according to the 
PAM50 gene classifier.
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the institutional archival cohort with an AUC of 0.93 vs 
0.81 for Ki67 alone (Youden’s index 0.73 vs 0.47; figure 4D 
and online supplemental figure 6B), highlighting that the 
model performs well also on routinely processed FFPE 
samples. The miR-100- based model was also challenged in 
the METABRIC dataset, which was split in a training and a 
validation set. Despite all the variables being quantified with 
different techniques compared with our prospective and 
retrospective studies, the ROC curves suggested the repro-
ducibility of the model (online supplemental figure 6C).
DISCUSSION
In this study, we sought to explore miR-100 as a predictor 
of endocrine responsiveness and prognosis in HR- pos-
itive/HER2- negative patients with breast cancer. We 
derived the rationale from our previous experimental 
evidence suggesting that ectopic expression of this 
miRNA was able to induce a phenotypic and functional 
change in models of basal- like breast cancer stem cells.27 
These included loss of stemness, expression of hormone 
receptor, and sensitivity to endocrine therapy. To pursue 
our aims, we used a widely adopted and validated clinical 
model consisting of the evaluation of tumour prolifera-
tion by Ki67 after a short exposure to endocrine therapy.32 
The rate of CCCA (post- treatment Ki67 ≤2.7%) found in 
postmenopausal patients was similar to what reported in 
the medical literature, with the additional information 
that no CCCA was observed in premenopausal patients 
receiving tamoxifen alone. One main finding of the study 
was that miR-100 is inversely correlated with both base-
line and post- treatment Ki67. In parallel, miR-100 expres-
sion was also higher in non- ductal histology, lower- grade 
tumours and luminal A tumours (online supplemental 
table 3). This corroborates the hypothesis that high levels 
of miR-100 characterise biologically less aggressive and 
more endocrine- responsive HR- positive tumours. Indeed, 
miR-100 was significantly and independently corre-
lated with CCCA in postmenopausal patients receiving 
aromatase inhibitors. The multivariable analysis also 
suggested that the Ki67 score before treatment is a strong 
Figure 4 A miR-100- based classifier predicts the luminal A molecular subtype. (A) Boxplots of miR-100 expression in 
Luminal A and B tumour biopsies classified by the PAM50 gene signature in the BC- P1-13, archival (B) and in the METABRIC 
(C) cohorts. The line within the box, boundaries and whiskers indicate median, IQR and 1.5 times the IQR, respectively. P 
values were calculated by the Mann- Whitney U test. (C, D) Receiver operating characteristic curves for the prediction of the 
luminal A subtype according to the multivariable logistic regression model (based on baseline Ki67 and miR100/target score) in 
the BC- P1-13 (C) and archival (D) cohorts. The performance of each model was evaluated as the area under the curve (AUC) 
and Youden’s index (J).
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predictor of a CCCA, meaning that tumours starting at 
lower levels of proliferation are more likely to achieve 
the post- treatment cut- off for CCCA. Notably, although 
the molecular phenotype (luminal A vs non- luminal A) 
was a strong predictor of CCCA in univariable analysis, it 
was not retained in the final multivariable model. Being 
Ki67 and miR-100 anticorrelated, there is concern that 
our multivariable analysis might not accurately resolve 
their respective contribution to the predictive power of 
the model. To partially overcome this issue and to include 
in the analysis the whole population enrolled in the 
BC- P1-13 study, we explored other definitions of prolif-
erative response. In particular, we considered the percent 
reduction in Ki67 values during short term exposure, 
which showed no correlation with baseline Ki67 (online 
supplemental figure 4). We found a significantly larger 
geometric mean reduction in the Ki67 score in tumours 
with high expression of miR-100 (≥the 75th percentile), 
providing further evidence of the predictive role of this 
miRNA with respect to response to endocrine therapy 
independently of baseline Ki67.
In line with the observed predictive role of miR-100, 
analyses conducted in the METABRIC and TCGA popula-
tions of patients with ER- positive breast cancer confirmed 
a strong association of high miR-100 expression and 
improved OS. Additionally, in the METABRIC dataset, 
which provides the PAM50 molecular subtypes, we found 
that miR-100 could prognostically stratify patients with 
luminal A tumours exposed to endocrine therapy. In these 
patients, miR-100 levels above the median were associated 
with a 45% reduction in the risk of death, an outstanding 
finding that deserves further investigation. Indeed, in the 
clinical practice, patients with operable luminal A tumours 
are considered as having an excellent long- term prognosis 
with endocrine therapy alone. However, here we show that 
the Luminal A patients can be stratified into prognostically 
different subgroups, and, according to our observation, 
miR-100 appears to be an informative biomarker to this aim. 
The anticorrelation between miR-100 levels and the expres-
sion of four out of five target genes previously reported to 
sustain endocrine therapy resistance suggests that the predic-
tive role of miR-100 may result from the simultaneous down-
regulation of multiple genes individually mediating tumour 
resistance. Moreover, we found evidence that high levels of 
miR-100 concur to the luminal A phenotype and we were 
able to develop and validate a signature based on miR-100, 
two of its target genes (PLK1 and FOXA1) and baseline 
Ki67 that predicted the luminal A molecular subtype with 
better performance than Ki67 alone. This is underlined 
by a higher and more reproducible Youden’s index, which 
captures the performance of a diagnostic test, associated to 
the miR-100- based classifier compared with the Ki67 score 
alone. We, thus believe, that this signature deserves to be 
further developed and validated in larger and independent 
series for its prognostic value in patients with HR- positive 
breast cancer receiving adjuvant treatment.
While our results are encouraging, pointing at miR-100 
as a potential new biomarker, we have to acknowledge 
some limitations that need being considered. First, a 
defined cut- off for miR-100 expression level able to 
dichotomise patients in responders and non- responders 
to primary endocrine therapy remains to be refined and 
confirmed in larger and independent patient cohorts. 
Second, the clinical translatability of miR-100 and its 
target genes as biomarkers relies on procedures which 
are not routinely performed in many Pathology Depart-
ments and that need to be standardised.
In conclusion, we demonstrated that high levels of 
miR-100 are associated with an endocrine- responsive 
phenotype in patients with luminal tumours undergoing 
primary endocrine therapy. We suggest that endocrine 
responsiveness likely results from the simultaneous low 
expression of genes that are related to endocrine resis-
tance, and that miR-100 could be an important player 
in modulating their expression. Being strongly related 
to endocrine responsiveness, miR-100 results also associ-
ated with long- term survival in patients with early breast 
cancer submitted to adjuvant endocrine therapy. The 
finding in molecularly defined luminal A tumours is 
striking and has relevant potential clinical implications. 
Finally, the expression of miR-100 and its target genes 
could be integrated in a simple and reproducible signa-
ture that was able to distinguish between molecularly 
defined luminal A and B tumours. Our findings support 
confirmatory studies in larger and independent datasets. 
Additionally, due to the suggested role as a biomarker 
for human cancers, like glioblastoma,13 oesophageal 
cancer14 or bladder carcinoma,15 34 a formal evaluation of 
serum miR-100 is warranted to explore this non- invasive 
modality in the management of in women with luminal 
breast cancer.
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